Literature DB >> 29296863

Management of thrombotic thrombocytopenic purpura without plasma exchange: the Jehovah's Witness experience.

James N George1,2, Steven A Sandler3, Joanna Stankiewicz3.   

Abstract

TTP in Jehovah's Witness patients has been managed successfully without PEX.This experience, plus new TTP treatments, may make it possible for patients who are not Jehovah's Witnesses to avoid PEX in the future.

Entities:  

Year:  2017        PMID： 29296863      PMCID： PMC5737137          DOI： 10.1182/bloodadvances.2017012351

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


  14 in total

1.  A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura.

Authors:  Marie Scully; Vickie McDonald; Jamie Cavenagh; Beverley J Hunt; Ian Longair; Hannah Cohen; Samuel J Machin
Journal:  Blood       Date:  2011-06-02       Impact factor: 22.113

2.  Pegylated bovine carboxyhaemoglobin utilisation in a thrombotic thrombocytopenic purpura patient.

Authors:  C Sam; P Desai; D Laber; A Patel; N Visweshwar; M Jaglal
Journal:  Transfus Med       Date:  2017-04-12       Impact factor: 2.019

3.  Survival and relapse in patients with thrombotic thrombocytopenic purpura.

Authors:  Johanna A Kremer Hovinga; Sara K Vesely; Deirdra R Terrell; Bernhard Lämmle; James N George
Journal:  Blood       Date:  2009-12-23       Impact factor: 22.113

4.  Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.

Authors:  G A Rock; K H Shumak; N A Buskard; V S Blanchette; J G Kelton; R C Nair; R A Spasoff
Journal:  N Engl J Med       Date:  1991-08-08       Impact factor: 91.245

5.  Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.

Authors:  Flora Peyvandi; Marie Scully; Johanna A Kremer Hovinga; Spero Cataland; Paul Knöbl; Haifeng Wu; Andrea Artoni; John-Paul Westwood; Magnus Mansouri Taleghani; Bernd Jilma; Filip Callewaert; Hans Ulrichts; Christian Duby; Dominique Tersago
Journal:  N Engl J Med       Date:  2016-02-11       Impact factor: 91.245

6.  Renal insufficiency and failure associated with immune globulin intravenous therapy--United States, 1985-1998.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1999-06-25       Impact factor: 17.586

7.  Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors.

Authors:  E A Sekul; E J Cupler; M C Dalakas
Journal:  Ann Intern Med       Date:  1994-08-15       Impact factor: 25.391

8.  ADAMTS13 content in plasma-derived factor VIII/von Willebrand factor concentrates.

Authors:  Flora Peyvandi; Pier M Mannucci; Carla Valsecchi; Silvia Pontiggia; Claudio Farina; Anastassios D Retzios
Journal:  Am J Hematol       Date:  2013-08-30       Impact factor: 10.047

9.  Successful treatment of congenital TTP with a novel approach using plasma-derived factor VIII.

Authors:  Swati Naik; Donald H Mahoney
Journal:  J Pediatr Hematol Oncol       Date:  2013-10       Impact factor: 1.289

10.  Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features.

Authors:  Jessica A Reese; Darrshini S Muthurajah; Johanna A Kremer Hovinga; Sara K Vesely; Deirdra R Terrell; James N George
Journal:  Pediatr Blood Cancer       Date:  2013-06-01       Impact factor: 3.167
View more
  5 in total

Review 1.  The remarkable diversity of thrombotic thrombocytopenic purpura: a perspective.

Authors:  James N George
Journal:  Blood Adv       Date:  2018-06-26

2.  Immune-mediated thrombotic thrombocytopenic purpura in a Jehovah's Witness - Effectiveness of incorporating extracorporeal immunoadsorption to caplacizumab, steroids and rituximab.

Authors:  Teresa Marta Cardesa-Salzmann; Bernhard Stephan; Arne Simon; Rhoikos Furtwängler; Dominik Schöndorf; Sabine Heine; Eyad Torfah; Margaux Lux; Sonja Meyer; Norbert Graf
Journal:  Clin Case Rep       Date:  2022-05-20

3.  Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura.

Authors:  X Long Zheng; Sara K Vesely; Spero R Cataland; Paul Coppo; Brian Geldziler; Alfonso Iorio; Masanori Matsumoto; Reem A Mustafa; Menaka Pai; Gail Rock; Lene Russell; Rawan Tarawneh; Julie Valdes; Flora Peyvandi
Journal:  J Thromb Haemost       Date:  2020-09-11       Impact factor: 5.824

4.  Successful Management of Thrombotic Thrombocytopenic Purpura in a Jehovah's Witness: An Individualized Approach With Joint Decision-Making.

Authors:  Ming Y Lim; Charles S Greenberg
Journal:  J Patient Exp       Date:  2019-02-14

5.  Complete recovery of deep venous thrombosis from Coombs (+) thrombotic thrombocytopenic purpura: case report.

Authors:  Mi Zhou; Jie Yin
Journal:  J Cardiothorac Surg       Date:  2022-03-21       Impact factor: 1.637
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.